全文获取类型
收费全文 | 31263篇 |
免费 | 2206篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 927篇 |
妇产科学 | 816篇 |
基础医学 | 4090篇 |
口腔科学 | 1297篇 |
临床医学 | 3867篇 |
内科学 | 5921篇 |
皮肤病学 | 536篇 |
神经病学 | 2695篇 |
特种医学 | 641篇 |
外科学 | 3371篇 |
综合类 | 258篇 |
一般理论 | 52篇 |
预防医学 | 3837篇 |
眼科学 | 576篇 |
药学 | 2112篇 |
1篇 | |
中国医学 | 134篇 |
肿瘤学 | 2090篇 |
出版年
2024年 | 37篇 |
2023年 | 350篇 |
2022年 | 588篇 |
2021年 | 1187篇 |
2020年 | 751篇 |
2019年 | 1154篇 |
2018年 | 1260篇 |
2017年 | 912篇 |
2016年 | 940篇 |
2015年 | 1102篇 |
2014年 | 1437篇 |
2013年 | 1860篇 |
2012年 | 2768篇 |
2011年 | 2733篇 |
2010年 | 1461篇 |
2009年 | 1193篇 |
2008年 | 2046篇 |
2007年 | 2066篇 |
2006年 | 1788篇 |
2005年 | 1713篇 |
2004年 | 1580篇 |
2003年 | 1299篇 |
2002年 | 1135篇 |
2001年 | 271篇 |
2000年 | 198篇 |
1999年 | 229篇 |
1998年 | 225篇 |
1997年 | 165篇 |
1996年 | 129篇 |
1995年 | 83篇 |
1994年 | 62篇 |
1993年 | 70篇 |
1992年 | 69篇 |
1991年 | 74篇 |
1990年 | 62篇 |
1989年 | 55篇 |
1988年 | 60篇 |
1987年 | 62篇 |
1986年 | 54篇 |
1985年 | 49篇 |
1984年 | 29篇 |
1983年 | 32篇 |
1982年 | 17篇 |
1981年 | 16篇 |
1980年 | 16篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1974年 | 15篇 |
1973年 | 17篇 |
1969年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
Polido-Pereira J Rodrigues AM Canhão H Saraiva F da Silva JA Fonseca JE 《Clinical rheumatology》2012,31(2):385-389
Primary biliary cirrhosis (PBC) is an autoimmune disease in which intrahepatic bile ducts are targeted by an immune-mediated injury. This disease tends to progress to fibrosis and cirrhosis with hepatic failure. The authors report a case of a 50-year-old rheumatoid arthritis (RA) patient, with erosions and seropositive for rheumatoid factor and anti-citrullinated peptide antibodies, with 18 years disease duration refractory to prednisolone and several disease-modifying antirheumatic drugs, either conventional or biological (adalimumab and etanercept). In April 2007, she started therapy with rituximab (RTX) with good European League Against Rheumatism response achieved 9 months later. In June 2008, she was admitted with intrahepatic cholestasis, steatorrhea, and spontaneous fractures of various ribs. After excluding cholelitiasis, as well as infectious and neoplastic diseases a liver biopsy was performed that was compatible with the diagnosis of PBC. The antinuclear antibodies (1/160) were positive as well as the antimitochondrial antibodies (1/640). Other antibodies were negative such as anti-SSA and anti-SSB. Afterwards, the patient started ursodesoxycholic acid 15 mg kg-1 day-1 with progressive improvement of cholestatic markers. A labial salivary gland biopsy was performed and showed findings compatible with the concomitant diagnosis of Sjögren’s syndrome. Based on this clinical report, a detailed review of the clinical aspects of PBC is presented as well as its association with other immune-mediated inflammatory diseases, particularly, with RA. 相似文献
972.
Araujo VP Aguiar-Oliveira MH Oliveira JL Rocha HM Oliveira CR Rodrigues TM Nunes MA Britto IM Ximenes R Barreto-Filho JA Meneguz-Moreno RA Pereira RM Valença EH Oliveira-Neto LA Vicente TA Blackford A Salvatori R 《European journal of endocrinology / European Federation of Endocrine Societies》2012,166(6):977-982
973.
Green TN Archary M Gordon ML Padayachi N Lie Y Anton ED Reeves JD Grobler A Bobat R Coovadia H Ndung'u T 《AIDS research and human retroviruses》2012,28(4):324-332
HIV-1 drug resistance monitoring in resource-poor settings is crucial due to limited drug alternatives. Recent reports of the increased prevalence of CXCR4 usage in subtype C infections may have implications for CCR5 antagonists in therapy. We investigated the prevalence of drug resistance mutations and CXCR4 coreceptor utilization of viruses from HIV-1 subtype C-infected children. Fifty-one children with virological failure during highly active antiretroviral therapy (HAART) and 43 HAART-naive children were recruited. Drug resistance genotyping and coreceptor utilization assessment by phenotypic and genotypic methods were performed. At least one significant drug resistance mutation was present in 85.4% of HAART-failing children. Thymidine analogue mutations (TAMs) were detected in 58.5% of HAART-failing children and 39.0% had ≥3 TAMs. CXCR4 (X4) or dual (R5X4)/mixed (R5, X4) (D/M)-tropic viruses were found in 54.3% of HAART-failing and 9.4% of HAART-naive children (p<0.0001); however, the HAART-failing children were significantly older (p<0.0001). In multivariate logistic regression, significant predictors of CXCR4 usage included antiretroviral treatment, older age, and lower percent CD4(+) T cell counts. The majority of genotypic prediction tools had low sensitivity (≤65.0%) and high specificity (≥87.5%) for predicting CXCR4 usage. Extensive drug resistance, including the high percentage of TAMs found, may compromise future drug choices for children, highlighting the need for improved treatment monitoring and adherence counseling. Additionally, the increased prevalence of X4/D/M viruses in HAART-failing children suggests limited use of CCR5 antagonists in salvage therapy. Enhanced genotypic prediction tools are needed as current tools are not sensitive enough for predicting CXCR4 usage. 相似文献
974.
Pediatric traumatic brain injury (TBI) is a major cause of acquired cognitive dysfunction in children. Hippocampal Brain Derived
Neurotrophic Factor (BDNF) is important for normal cognition. Little is known about the effects of TBI on BDNF levels in the
developing hippocampus. We used controlled cortical impact (CCI) in the 17 day old rat pup to test the hypothesis that CCI
would first increase rat hippocampal BDNF mRNA/protein levels relative to SHAM and Na?ve rats by post injury day (PID) 2 and
then decrease BDNF mRNA/protein by PID14. Relative to SHAM, CCI did not change BDNF mRNA/protein levels in the injured hippocampus
in the first 2 days after injury but did decrease BDNF protein at PID14. Surprisingly, BDNF mRNA decreased at PID 1, 3, 7
and 14, and BDNF protein decreased at PID 2, in SHAM and CCI hippocampi relative to Na?ve. In conclusion, TBI decreased BDNF
protein in the injured rat pup hippocampus 14 days after injury. BDNF mRNA levels decreased in both CCI and SHAM hippocampi
relative to Na?ve, suggesting that certain aspects of the experimental paradigm (such as craniotomy, anesthesia, and/or maternal
separation) may decrease the expression of BDNF in the developing hippocampus. While BDNF is important for normal cognition,
no inferences can be made regarding the cognitive impact of any of these factors. Such findings, however, suggest that meticulous
attention to the experimental paradigm, and possible inclusion of a Na?ve group, is warranted in studies of BDNF expression
in the developing brain after TBI. 相似文献
975.
Many countries with heavy HIV and alcohol burdens do not fully recognize these epidemics as intrinsically interconnected. Missed opportunities for synergistic prevention and treatment of HIV and alcohol abound.Few HIV policies, services for HIV prevention or research projects adequately address alcohol-HIV harms or include alcohol use as an HIV risk factor. 相似文献
976.
Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification 总被引:1,自引:0,他引:1
Aims To conduct a randomized, controlled trial of abstinence‐contingent recovery housing delivered with or without intensive day treatment among individuals exiting residential opioid detoxification. Design Random assignment to one of three conditions: recovery housing alone (RH), abstinence‐contingent recovery housing with reinforcement‐based treatment RBT (RH + RBT) or usual care (UC). RH and RH + RBT participants received 12 weeks of paid recovery housing contingent upon drug abstinence. RH + RBT participants also received 26 weeks of RBT, initiated concurrently with recovery housing. Assessments were conducted at 1, 3 and 6 months after treatment enrollment. Setting Out‐patient drug‐free substance abuse treatment program in Baltimore, Maryland. Participants Patients (n = 243) who completed medication‐assisted opioid detoxification. Measurements Primary outcome was drug abstinence (opioid‐ and cocaine‐negative urine and no self‐reported opioid or cocaine use in the previous 30 days). Secondary outcomes included abstinence at all time‐points (1, 3 and 6 months), days in recovery housing and employment. Findings Overall rates of drug abstinence were 50% for RH + RBT, 37% for RH and 13% for UC (P < 0.001). At 6 months, RH + RBT participants remained more likely to meet abstinence criteria than UC participants (37% versus 20%, P = 0.016). Length of stay in recovery housing mediated abstinence outcomes and was longer in RH + RBT (49.5 days) than in RH (32.2 days; P < 0.002). Conclusions Abstinence‐contingent recovery housing improves abstinence in opioid‐dependent adults following medication‐assisted detoxification. The addition of intensive ‘reinforcement‐based treatment’ behavioural counseling further improves treatment outcomes, in part by promoting longer recovery house stays. 相似文献
977.
Cavalcante Morais T Cavalcante Lopes S Bezerra Carvalho KM Rodrigues Arruda B Correia de Souza FT Salles Trevisan MT Rao VS Almeida Santos F 《World journal of gastroenterology : WJG》2012,18(25):3207-3214
AIM: To investigate the effects of mangiferin on gastrointestinal transit (GIT) in normal and constipated mice, together with the possible mechanism.METHODS: Intragastrically-administered charcoal meal was used to measure GIT in overnight starved Swiss mice. In the first experiments, mangiferin (3 mg/kg, 10 mg/kg, 30 mg/kg, and 100 mg/kg, po) or tegaserod (1 mg/kg, ip) were administered 30 min before the charcoal meal to study their effects on normal transit. In the second series, mangiferin (30 mg/kg) was tested on delayed GIT induced by several different pharmacological agonists (morphine, clonidine, capsaicin) or antagonists (ondansetron, verapamil, and atropine) whereas in the third series, mangiferin (30 mg/kg, 100 mg/kg and 300 mg/kg) or tegaserod (1 mg/kg) were tested on 6 h fecal pellets outputted by freely fed mice. The ratio of wet to dry weight was calculated and used as a marker of fecal water content.RESULTS: Mangiferin administered orally significantly (P < 0.05) accelerated GIT at 30 mg/kg and 100 mg/kg (89% and 93%, respectively), similarly to 5-hydroxytryptamine4 (5-HT4) agonist tegaserod (81%) when compared to vehicle-treated control (63%). Co-administered mangiferin (30 mg/kg) totally reversed the inhibitory effect of opioid agonist morphine, 5-HT3-receptor antagonist ondansetron and transient receptor potential vanilloid-1 receptor agonist capsaicin on GIT, but only to a partial extent with the GIT-delay induced by α2-adrenoceptor agonist clonidine, and calcium antagonist verapamil. However, co-administered atropine completely blocked the stimulant effect of mangiferin on GIT, suggesting the involvement of muscarinic acetylcholine receptor activation. Although mangiferin significantly enhanced the 6 h fecal output at higher doses (245.5 ± 10.43 mg vs 161.9 ± 10.82 mg and 227.1 ± 20.11 mg vs 161.9 ± 10.82 mg of vehicle-treated control, at 30 and 100 mg/kg, P < 0.05, respectively), the effect of tegaserod was more potent (297.4 ± 7.42 mg vs 161.9 ± 10.82 mg of vehicle-treated control, P < 0.05). Unlike tegaserod, which showed an enhanced water content in fecal pellets (59.20% ± 1.09% vs 51.44% ± 1.19% of control, P < 0.05), mangiferin evidenced no such effect, indicating that it has only a motor and not a secretomotor effect.CONCLUSION: Our data indicate the prokinetic action of mangiferin. It can stimulate the normal GIT and also overcome the drug-induced transit delay, via a cholinergic physiological mechanism. 相似文献
978.
Stern C Martinot-Peignoux M Ripault MP Boyer N Castelnau C Valla D Marcellin P 《World journal of gastroenterology : WJG》2012,18(23):2966-2972
AIM: To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients.METHODS: Out of 1228 CHC patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV), 165 (13%) had a relapse. Among these, 62 patients were retreated with PEG-IFN-α2a or -α2b and RBV. Clinical, biological, virological and histological data were collected. Initial doses and treatment modifications were recorded. The efficacy of retreatment and predictive factors for SVR were analyzed.RESULTS: An SVR was achieved in 42% of patients. SVR was higher in young (< 50 years) (61%) than old patients (27%) (P = 0.007), and in genotype 2 or 3 (57%) than in genotype 1 or 4 (28%) patients (P = 0.023). Prolonging therapy for at least 24 wk more than the previous course was associated with higher SVR rates (53% vs 28%, P = 0.04). Also, a better SVR rate was observed with RBV dose/body weight > 15.2 mg/kg per day (70% vs 35%, P = 0.04). In logistic regression, predictors of a response were age (P = 0.018), genotype (P = 0.048) and initial RBV dose/body weight (P = 0.022). None of the patients without a complete early virological response achieved an SVR (negative predictive value = 100%).CONCLUSION: Retreatment with PEG-IFN/RBV is eff-ective in genotype 2 or 3 relapsers, especially in young patients. A high dose of RBV seems to be important for the retreatment response. 相似文献
979.
980.